retatrutide trial update october 2025 Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced. In Retatrutide: What It Is &

If you're concerned about your child's metabolism, insulin resistance, weight, or overall health, you don't have to navigate it alone

Commenting on the study, Hannah Beba, clinical lead for obesity at the West Yorkshire Health and Care Partnership, called the retatrutide topline results genuinely striking, noting that the 30% weight loss was a level long associated with bariatric surgery

Lilly has not yet submitted its application, the FDA has not yet accepted it for review, and no approval has been granted

The STEP-HFpEF DM trial confirmed similar benefits in T2DM patients [56]

A warm bath : Relax and unwind

Aging Dis